Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

• US 7,749,494 B2
• Filed: 05/11/2001
• Issued: 07/06/2010
• Est. Priority Date: 05/11/2000
• Status: Active Grant

• Current Assignee: Armistice Capital Master Fund Ltd. (Armistice Capital LLC), CJ Bioscience Incorporated
• Original Assignee: Institut National de La Recherche Agronomique
• Inventors: Renaud, Michel, Bernalier, Annick
• Primary Examiner(s): Weber; Jon P
• Assistant Examiner(s): Srivastava; Kailash C
• Application Number:
  US10/275,706
• Publication Number:
  US 20030147858A1
• Time in Patent Office: 3,343 Days
• Field of Search: 424/93.4
• US Class Current: 424/93.4
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: Y10S 435/822 using bacteria or actinomycetales

Abstract

The invention concerns the use of non-pathogenic hydrogenotrophic acetogenic bacterial strains for preparing a composition for treating or preventing gastrointestinal disorders associated with productions of digestive gases and/or for modulating the microbial balance of the digestive ecosystem in a mammal. The invention also concerns said pharmaceutical or food compositions, and the methods for monitoring and preparing said strains.

Claims

1. A method of treating gastrointestinal disorders related to the production of hydrogen in the gastrointestinal tract in a mammal, the method comprising administering to a mammal in need thereof a composition comprising Ruminococcus hydrogenotrophicus wherein said method does not remove any existing enteric microbial flora prior to administering said composition orally or rectally and wherein said composition modulates the balance of the microbial flora in the colon and reduces the amount of gaseous hydrogen produced by the existing flora.

2. The method of claim 1, wherein Ruminococcus hydrogenotrophicus remains active in the colon.

3. The method of claim 1, wherein the composition also comprises a pharmaceutically acceptable carrier.

4. The method of claim 1, wherein said mammal is human, canine or feline.

5. The method of claim 1, wherein said gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, excessive flatulence, meteorism, bloating and abdominal pain.